Amisulpride Augmentation in Patients with Schizophrenia Partially Responsive or Unresponsive to Clozapine. A Randomized, Double-Blind, Placebo-Controlled Trial

Abstract

Introduction: Only limited data are available on the effectiveness of augmented antipsychotics to clozapine therapy in chronic schizophrenia. We conducted a randomized, double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of augmentation with the atypical neuroleptic amisulpride to clozapine in a small sample group of patients.

Methods: 16 patients with the DSM-IV diagnosis of chronic schizophrenia and partially responsive to clozapine participated in this pilot study. Patients on a steady dose of clozapine randomly received either clozapine and amisulpride 400 mg/day (n=7) or clozapine and amisulpride 600 mg/day (n=6) or clozapine and placebo for 6 weeks (n=3). Efficacy measures were BPRS, CGI, GAF and MADRS score. Side effects and prolactin levels were obtained. Primary outcome measure were BPRS score changes.

Results: The beneficial effect of augmented amisulpride at a daily dose of 600 mg was observed in the mean scores of secondary outcome measures, as assessed by GAF, CGI and MADRS. Measures of primary objectives failed to improve significantly. No reduction in BPRS total score was achieved due to lack of power of the study, whereas the BPRS subscore “activity” had a tendency to improve. Amisulpride was more beneficial in a higher than a lower dose. No severe side-effects occurred, but tremor, bradykinesia, akathisia and elevated prolactin levels were recorded.

Discussion: Augmented amisulpride improved the global outcome of patients suffering from chronic schizophrenia in this pilot study and tended to be a helpful treatment option in cases of partial or non-responsiveness to clozapine. Limitations emerge from the small sample size and lack of power. Further investigation requires a larger number of patients to be included.

References

• 1 Agelink M, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia.  Am J Psychiatry. 2004;  161 924-925
• 2 Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI. et al . A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.  J Clin Psychiatry. 2005;  66 63-72
• 3 Bergemann N, Kress KR, Frick A, Kopitz J. Amisulpride has no effect on plasma clozapine concentrations.  J Clin Psychopharmacol. 2005;  25 494-498
• 4 Buchanan RW. Clozapine: efficacy and safety.  Schizophr Bull. 1995;  21 579-591
• 5 Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence.  J Psychopharmacol. 2006;  , (Epub ahead of print)
• 6 Cook B, Hoogenboom G. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia.  Australasian Psychiatry. 2004;  12 74-76
• 7 Croissant B, Hermann D, Olbrich R. Reduction of side effects by combining clozapine with amisulpride: Case report and short review of clozapine-induced hypersalivation.  Pharmacopsychiatry. 2005;  38 38-39
• 8 Demling JH, Huang ML, Remmerie B. et al . Pharmacokinetics and safety of combination therapy with lithium and risperidone.  Pharmacopsychiatry. 2006;  39 230-231
• 9 Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences.  Behavior Research Methods. 2007;  39 175-191
• 10 Flynn SW, MacEwan GW, Altman S, Kopala LC. et al . An open label comparison of clozapine and risperidone in treatment-resistant schizophrenia.  Pharmacopsychiatry. 1998;  31 25-29
• 11 Freudenreich O, Henderson DC, Walsh JP. et al . Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.  Schizophr Res. 2007;  92 90-94
• 12 Gaebel W, Falkai P. Behandlungsleitlinie Schizophrenie. Reihe S3 Praxisleitlinien in Psychiatrie und Psychotherapie, Band 1. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde. (Hrsg.). Darmstadt, Steinkopff 2006
• 13 Genc Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study.  Adv Ther. 2007;  24 1-13
• 14 George S, Cowan C. Effectiveness of amisulpride augmentation of clozapine in a non-responder to either drug alone: a case-report.  Acta Psychiatr Scand. 2005;  111 163
• 15 Honer WG, Thornton AE, Chen EY. et al . Clozapine alone versus clozapine and risperidone with refractory schizophrenia.  N Engl J Med. 2006;  354 472-482
• 16 Josiassen RC, Joseph A, Kohegyi E. et al . Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.  Am J Psychiatr. 2005;  163 130-136
• 17 Kaempf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: A promising therapeutic approach to refractory schizophrenic symptoms.  Pharmacopsychiatry. 2005;  38 39-40
• 18 Kapur S, Roy P, Daskalakis J. et al . Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.  Am J Psychiatry. 2001;  158 311-314
• 19 Kivircik Akdede BB, Anil Yagcioglu AE, Alptekin K. et al . A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.  J Clin Psychiatry. 2006;  67 1912-1919
• 20 Lerner V, Bergmann J, Borokhov A. et al . Augmentation of amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy.  Clin Neuropharmacol. 2005;  28 66-71
• 21 Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual “atypical” antipsychotic: A meta-analysis of randomised controlled trials.  Am J Psychiat. 2002;  159 180-190
• 22 Lewis SW, Barnes TR, Davies L, Murray R. et al . Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.  Schizophr Bull. 2006;  32 715-723
• 23 Lewis SW, Davies L, Jones PB. et al . Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.  Health Technol Assess. 2006;  10 1-182
• 24 Matthiason P, Erlandsson K, Costa D. et al . Amisulpride augmentation of clozapine and striatal dopamine D2 receptor binding potential. A 123-I-IBZM study.  Schizophrenia Research. 2003;  53 ((S3)) 208
• 25 Matthiasson P, Costa DC, Erlandsson K. et al . Increased dopamine D2 receptor binding in the basal ganglia after augmenting clozapine treatment with amisulpride. An 123-I-IBZM SPECT-study.  J Psychopharmacol. 2000;  14S A57
• 26 Moeller HJ. Amisulpride: a review of its efficacy in schizophrenia.  Acta Psychiat Scand Suppl. 2000;  400 17-22
• 27 Molina V, Sanz J, Sarramea F, Palomo T. Marked hypofrontality in clozapine-responsive patients.  Pharmacopsychiatry. 2007;  40 157-162
• 28 Müller MJ, Regenbogen B, Sachse J. et al . Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.  Pharmacopsychiatry. 2006;  39 41-46
• 29 Munro J, Matthiasson P, Osborne S. et al . Amisulpride augmentation of clozapine: an open, non-randomized study in patients with schizophrenia partially responsive to clozapine.  Acta Psychiatr Scand. 2004;  110 241-242
• 30 Pessina A, Turlizzi E, Bonomi A. et al . In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU).  Pharmacopsychiatry. 2006;  39 20-22
• 31 Procopio M. Sulpiride augmentation on schizophrenia.  Br J Psychiatry. 1998;  2 449-450
• 32 Reznik I, Yavin I, Stryjer R, Spivak B. et al . Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study.  Pharmacopsychiatry. 2004;  37 52-56
• 33 Saletu B, Grunberger J, Linzmayer L, Anderer P. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.  Pharmacopsychiatry. 1987;  20 12-27
• 34 Shiloh R, Zemishlany Z, Aizenberg D. et al . Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study.  Eur Psychiatry. 1997;  12 152-155
• 35 Shiloh R, Zemishlany Z, Aizenberg D. et al . Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.  Br J Psychiat. 1997;  171 569-573
• 36 Stubbs JH, Haw CM, Staley CJ. et al . Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine.  Acta Psychiatr Scand. 2000;  102 390-393
• 37 Zink M, Dressing H. Augmentation of clozapine with atypical antipsychotic substances.  Current Psychiatry Reviews. 2005;  1 165-172
• 38 Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses.  Eur Psychiatry. 2004;  19 56-58
• 39 Zink M, Knopf U, Henn FA, Thome J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia - case reports and review of the literature.  Pharmacopsychiatry. 2004;  37 26-31
• 40 Zink M, Knopf U, Mase E, Kuwilsky A, Deuschle M. Duloxetine treatment of major depressive episodes in the course of psychotic disorders.  Pharmacopsychiatry. 2006;  39 109-111

Correspondence